ReviewmBio2026
A brief historical perspective of antimicrobial resistance in India.
Review in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is the ability of microbes to survive exposure to antimicrobials that were once effective against them. This is a major global crisis and public health challenge of the 21st century that is declared as a silent pandemic, with India among other countries considered one of the hotspots [R. Laxminarayan, A. Duse, C. Wattal, A. K. M. Zaidi, et al., Lancet Infect Dis 13:1057-1098, 2013, https://doi.org/10.1016/S1473-3099(13)70318-9]. The evolution of AMR in modern India's context is embedded in a complex interplay of the timing of antibiotic introduction, a growing dense population, cultural inheritances, infectious disease burden, developing health systems, evolving drug market regulations, environmental and animal sector drivers, socioeconomic factors, and policy/implementation gaps. Central to this discussion are the human patient, animal, and environmental aspects of antibiotic overuse from the historical aspects of AMR in India broadly tracing from early antibiotic use to the current "One Health" challenge. It highlights cultural factors, the evolution of surveillance systems, policy responses, India's efforts, and key lessons in antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.